The COP also serves as a referral center for the management of nonmelanoma skin cancer, including:

- Squamous cell carcinomas in immunocompetent and immunosuppressed patients
- Merkel cell carcinoma
- Cutaneous lymphomas, including CD30 lymphoproliferative diseases
- Other epidermal, appendageal, and undifferentiated cutaneous malignancies

Patients at risk for melanoma, particularly those with genetic risk, multiple nevi, or atypical nevi, may be concerned about developing melanoma. Patients at risk for other skin cancers, including immunosuppressed patients, are also comprehensively evaluated in the program, receiving care from dermatologists experienced in the surveillance of these complex phenotypes. Patients and family members also receive comprehensive skin cancer risk-reduction education. We offer total body and/or regional digital photographs (TBDP) to candidate patients to facilitate a more accurate follow up of atypical pigmented lesions or to patients with an overall complex cutaneous examination.
The Cutaneous Oncology Program (COP) at the University of Arizona Cancer Center offers exceptional care to patients with a wide variety of cutaneous malignancies. We provide patients with “one-stop” comprehensive, multidisciplinary clinical care by nationally and internationally known experts in:

- Dermatology
- Medical oncology
- Surgical oncology
- Head and neck surgery (ENT)
- Pathology
- Radiation oncology
- Nuclear medicine
- Behavioral science
- Public health

The multidisciplinary strengths of our program are leveraged to maximize treatment options and likelihood of response. Our experts use a team approach, working closely with referring physicians and community providers to create a plan of care and follow up for individual patients, and to deliver expert advice — all in a state-of-the-art facility. The COP tumor board meets weekly to review individual cases as needed. Management of malignant melanoma in all stages remains one of the COP’s areas of greatest expertise. For patients with locally advanced or metastatic disease, we provide the widest variety of conventional and experimental treatments, including:

- Surgical and radiation treatment
- Targeted therapy
- Immunotherapy and checkpoint inhibitors
- Intralesional treatment
- Vaccine therapy
- Chemotherapy
- Robust clinical trial portfolio with novel therapeutic approaches